Curriculum
Module 08 · 60 min

Cardiometabolic Change After 50

Body composition, lipids and blood pressure shift with the transition — independently of ageing.

CardiometabolicPrimary care track
Module progress0%
Quiz 0/3Cards 0/5Claims 0/6
Learning objectives

By the end of this module you will be able to

  • L01Explain that visceral adiposity increases across the transition independent of total weight change.
  • L02Include pregnancy history and age at menopause in every midlife cardiovascular risk assessment.
  • L03Interpret the lipid shift using ApoB or non-HDL cholesterol rather than LDL-C alone.
  • L04Describe how MHT's cardiovascular effect varies with time since menopause.
  • L05Identify why women with ACS present later and are investigated less.
Scope

Topics covered

01Visceral fat redistribution independent of weight gain
02The adverse lipid shift: LDL particle number, Lp(a) and ApoB
03Blood pressure trajectory and why women are under-treated
04Sex-specific risk enhancers: pre-eclampsia, gestational diabetes, preterm birth, POI
05Atypical presentation and diagnostic delay in acute coronary syndromes
06MHT and cardiovascular risk by timing
07What lifestyle intervention actually achieves at this stage
Module narrative

How this plays out in practice

Primary care view· your track

Treat the menopause consultation as a cardiovascular checkpoint. Measure waist, blood pressure sitting properly, HbA1c and a lipid profile including non-HDL. Ask three questions rarely asked: age at menopause, any hypertension or diabetes in pregnancy, and any preterm birth. Address blood pressure and lipids on their own merits — MHT decisions are separate.

Specialist view

Where risk is intermediate, coronary artery calcium scoring and Lp(a) measurement help reclassify. In women with POI or early menopause, cardiovascular risk assessment should start early and hormone therapy is part of risk mitigation rather than a risk factor. In women with established CVD who need symptom control, prefer non-hormonal therapy or transdermal at the lowest effective dose after cardiology discussion.

Advanced note

Disentangling chronological ageing from ovarian ageing requires within-woman longitudinal designs anchored to the FMP. SWAN's time-anchored models show LDL-C and ApoB rise sharply in the year around the FMP — a pattern inconsistent with linear ageing and consistent with an ovarian-hormone-driven effect. Note that visceral fat gain and the lipid shift are partly independent pathways, so treating one does not neutralise the other.

Expected takeaways

What you should walk away believing

  • →SWAN showed visceral fat rises sharply across the transition even when body weight is stable — waist measurement outperforms weight for tracking.
  • →Age at menopause under 45 is an independent cardiovascular risk factor and belongs in the risk conversation.
  • →Adverse pregnancy outcomes decades earlier are recognised risk enhancers in current prevention guidelines and are almost never recorded.
  • →MHT is not indicated for cardiovascular prevention — but neither is it a cardiovascular contraindication in appropriately selected early postmenopausal women.
  • →Statin under-prescription and under-titration in women is a persistent, measurable disparity.
Myth-buster

What patients — and colleagues — get wrong

The claim

“Menopausal weight gain is inevitable and caused by oestrogen loss.”

Reality

Total weight gain in midlife tracks chronological ageing and declining activity more than menopausal status; what the transition changes is fat distribution — a shift towards visceral, android deposition. That distinction matters for both counselling and measurement: track waist circumference, not just the scale.

Graded claims

Evidence grading for this module

B

Visceral adiposity increases across the menopause transition independent of ageing

Supported in defined populations — SWAN and longitudinal imaging cohorts.

B

Menopause before age 45 is an independent cardiovascular risk factor

Supported in defined populations — Consistent large cohort and meta-analytic data.

B

Adverse pregnancy outcomes are cardiovascular risk enhancers

Supported in defined populations — Endorsed in ACC/AHA and ESC prevention guidelines.

F

MHT should be prescribed for primary prevention of coronary disease

Refuted or actively misleading — Not an indication in any major guideline.

B

Transdermal estradiol has a neutral effect on triglycerides compared with oral

Supported in defined populations — Pharmacological first-pass effect, consistently demonstrated.

A

Statins are equally effective for secondary prevention in women and men

Established — RCT / guideline-grade — CTT collaboration individual-participant meta-analysis.

Evidence summary

Graded claims, key takeaways and sources for this module.

Open printable summary
Clinical vignettes

Apply it in clinic

The 15-minute menopause consult as a risk checkpoint

A 53-year-old presents for MHT review. BP 148/92 on two readings, waist 96 cm, HbA1c 43 mmol/mol, non-HDL 4.6 mmol/L. She had pre-eclampsia at 29.

What is the highest-value action in this consultation?

Self-assessment

Check your recall

Q1

Which measurement best captures the metabolically relevant change across the transition?

Q2

Which history item is a recognised cardiovascular risk enhancer that is rarely recorded?

Q3

A 55-year-old with hypertriglyceridaemia needs MHT. Preferred route?

Flashcards

Retrieval practice

Card 1 / 5
Reviewed 0 / 5
Glossary

Terms used in this module

Risk enhancer
A factor that shifts management when 10-year risk is intermediate, including sex-specific factors such as pre-eclampsia and early menopause.
ApoB
Apolipoprotein B — one particle per atherogenic lipoprotein; a better exposure measure than LDL-C when triglycerides are raised.
Android fat distribution
Central/visceral fat pattern that increases after the menopause transition.
Primary sources

Read the evidence yourself